First oncolytic virus approved for melanoma immunotherapy

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

(2015) Lorenzo Galluzzi et al.   CANCER CELL

Oncolytic Virus Immunotherapy for Melanoma

(2015) Neal Dharmadhikari et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

T-VEC oncolytic viral therapy shows promise in melanoma

(2015) David Killock   Nature Reviews Clinical Oncology

Oncolytic viruses get a boost with first FDA-approval recommendation

(2015) Elie Dolgin   NATURE REVIEWS DRUG DISCOVERY

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

Classification of current anticancer immunotherapies

(2015) Lorenzo Galluzzi et al.   Oncotarget

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015

(2014) L Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation

(2014) Lotte Spel et al.   OncoImmunology

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy

(2014) Samuel T Workenhe et al.   OncoImmunology

Healing after death: antitumor immunity induced by oncolytic adenoviral therapy

(2014) Hong Jiang et al.   OncoImmunology

Trial Watch: Radioimmunotherapy for oncological indications

(2014) Norma Bloy et al.   OncoImmunology

Trial Watch

(2014) Fernando Aranda et al.   OncoImmunology

Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+T-cell response, prominent infiltration of CD8+lymphocytes and Th1 type polarization

(2014) Tuuli Ranki et al.   OncoImmunology

Trial watch

(2014) Erika Vacchelli et al.   OncoImmunology

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses

(2014) Shashi Gujar et al.   OncoImmunology

Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death

(2014) Encouse B Golden et al.   OncoImmunology

Trial Watch:

(2014) Jonathan Pol et al.   OncoImmunology

Consensus guidelines for the detection of immunogenic cell death

(2014) Oliver Kepp et al.   OncoImmunology

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

(2013) Laurence Zitvogel et al.   IMMUNITY

Cancer immunotherapy turns viral

(2013) Lorenzo Galluzzi et al.   OncoImmunology

Trial Watch

(2013) Erika Vacchelli et al.   OncoImmunology

Trial watch

(2013) Erika Vacchelli et al.   OncoImmunology

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Clinical Development of Oncolytic Viruses in China

(2012) Min Liang   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

Trial watch

(2012) Erika Vacchelli et al.   OncoImmunology

Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus

(2011) Raymund R. Razonable   MAYO CLINIC PROCEEDINGS

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

(2010) Howard L Kaufman et al.   Future Oncology

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

(2009) Howard L. Kaufman et al.   ANNALS OF SURGICAL ONCOLOGY

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

(2009) Neil N. Senzer et al.   JOURNAL OF CLINICAL ONCOLOGY